Unknown

Dataset Information

0

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.


ABSTRACT: The activation and recruitment of CD4(+) T cells are critical for the development of efficient antitumor immunity and may allow for the optimization of current cancer immunotherapy strategies. Searching for more optimal and selective targets for CD4(+) T cells, we have investigated phosphopeptides, a new category of tumor-derived epitopes linked to proteins with vital cellular functions. Although MHC I-restricted phosphopeptides have been identified, it was previously unknown whether human MHC II molecules present phosphopeptides for specific CD4(+) T cell recognition. We first demonstrated the fine specificity of human CD4(+) T cells to discriminate a phosphoresidue by using cells raised against the candidate melanoma antigen mutant B-Raf or its phosphorylated counterpart. Then, we assessed the presence and complexity of human MHC II-associated phosphopeptides by analyzing 2 autologous pairs of melanoma and EBV-transformed B lymphoblastoid lines. By using sequential affinity isolation, biochemical enrichment, mass spectrometric sequencing, and comparative analysis, a total of 175 HLA-DR-associated phosphopeptides were characterized. Many were derived from source proteins that may have roles in cancer development, growth, and metastasis. Most were expressed exclusively by either melanomas or transformed B cells, suggesting the potential to define cell type-specific phosphatome "fingerprints." We then generated HLA-DRbeta1*0101-restricted CD4(+) T cells specific for a phospho-MART-1 peptide identified in both melanoma cell lines. These T cells showed specificity for phosphopeptide-pulsed antigen-presenting cells as well as for intact melanoma cells. This previously undescribed demonstration of MHC II-restricted phosphopeptides recognizable by human CD4(+) T cells provides potential new targets for cancer immunotherapy.

SUBMITTER: Depontieu FR 

PROVIDER: S-EPMC2715484 | biostudies-other | 2009 Jul

REPOSITORIES: biostudies-other

altmetric image

Publications

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.

Depontieu Florence R FR   Qian Jie J   Zarling Angela L AL   McMiller Tracee L TL   Salay Theresa M TM   Norris Andrew A   English A Michelle AM   Shabanowitz Jeffrey J   Engelhard Victor H VH   Hunt Donald F DF   Topalian Suzanne L SL  

Proceedings of the National Academy of Sciences of the United States of America 20090706 29


The activation and recruitment of CD4(+) T cells are critical for the development of efficient antitumor immunity and may allow for the optimization of current cancer immunotherapy strategies. Searching for more optimal and selective targets for CD4(+) T cells, we have investigated phosphopeptides, a new category of tumor-derived epitopes linked to proteins with vital cellular functions. Although MHC I-restricted phosphopeptides have been identified, it was previously unknown whether human MHC I  ...[more]

Similar Datasets

| S-EPMC1595446 | biostudies-literature
| S-EPMC2904831 | biostudies-literature
| S-EPMC4071620 | biostudies-literature
| S-EPMC1851603 | biostudies-literature
| S-EPMC2241739 | biostudies-literature
| S-EPMC8356565 | biostudies-literature
| S-EPMC9894575 | biostudies-literature
| S-EPMC4351420 | biostudies-literature
| S-EPMC3888030 | biostudies-literature
| S-EPMC8741298 | biostudies-literature